N-Acetyl Semax Amidate and Semax: what the two extra caps change

Semax is already a modified peptide. N-Acetyl Semax Amidate is Semax modified twice more. Both modifications sit at the ends of the molecule, both are standard moves in peptide chemistry, and knowing what each one does accounts for the entire difference between the two names.

This article is chemistry, published as reading. This catalogue carries Semax; it does not carry the acetylated, amidated form, and nothing below should be read as an offer of it.

What Semax already is

Semax (CAS 80714-61-0) is a heptapeptide, Met-Glu-His-Phe-Pro-Gly-Pro, with the formula C37H51N9O10S and a molecular weight near 814. The first four residues are lifted directly from adrenocorticotropic hormone. The trailing Pro-Gly-Pro is not — it was added deliberately.

The reason it was added is that native ACTH(4-10) is degraded in plasma almost immediately. The proline-rich tail resists that degradation substantially, and the resulting peptide keeps the neurotropic activity attributed to the parent fragment while losing its hormonal activity. Semax was developed at the Institute of Molecular Genetics in Moscow and has been studied in Russian clinical research for stroke and cognitive indications for several decades.

Two facts about that literature belong beside it. Semax is a registered medicine in Russia and is approved nowhere else — not by Health Canada, not by the FDA, not by the EMA. And most of the work behind the Russian registration is published in Russian-language journals and has not been replicated outside that tradition. The accessible end of that literature is rodent mechanism work on gene expression and on brain-derived neurotrophic factor.

So the baseline molecule is itself a stability modification of something shorter-lived. The acetylated, amidated version continues the same project.

The two additional modifications

N-terminal acetylation. The free amino terminus of a peptide carries a positive charge, and it is the structure aminopeptidases recognise before they cleave. Capping it with an acetyl group removes both the charge and the recognition site at once. This is among the most common stabilising modifications in peptide chemistry, for the unglamorous reason that it is cheap, reliable and easy to characterise.

C-terminal amidation. The other end carries a free carboxyl group with a negative charge. Converting it to an amide removes that charge and blocks carboxypeptidase cleavage. It also brings the molecule closer to how many of the body's own neuropeptides are terminated — amidation is a genuine enzymatic step in neuropeptide maturation, not purely a synthetic trick, which is part of why chemists reach for it.

Together the two cap both ends. The peptide backbone between them is untouched: same seven residues, same order, same side chains.

The arithmetic checks out

N-Acetyl Semax Amidate has the formula C39H54N10O10S, with PubChem CID 172638603 and a molecular weight near 855. Set that against Semax's C37H51N9O10S and the difference is two carbons, three hydrogens and one nitrogen more, with the oxygen count unchanged.

That is exactly what the two modifications predict. Acetylation adds C2H2O net. Amidation swaps a hydroxyl oxygen for an amine nitrogen, adding a nitrogen and a hydrogen and removing an oxygen. Add them up and the oxygens cancel. The mass difference, about 41, is the acetyl group's 42 less the one unit amidation subtracts.

Unlike Semax, it has no clean single CAS registry entry. That absence is informative in itself: a registry number is assigned when a substance has enough of a documentary trail to need one, and this molecule is new enough not to have accumulated that trail.

Stable is not a synonym for potent

The expected consequence of capping both ends is greater resistance to enzymatic degradation, and therefore a longer functional window. That is a well-established principle, and it is the part of the claim that holds up.

The leap worth refusing is the one from 'more stable' to 'stronger'. Those are different statements about different properties. Terminal capping reliably improves stability. Whether it improves activity depends on whether the termini were involved in receptor binding in the first place, and for this peptide that is not firmly established in published work. If the termini turn out to be part of what the target recognises, capping them can reduce activity rather than increase it. Changing how long a molecule survives changes exposure, and exposure can move in a direction a protocol did not intend.

Suppliers routinely present the acetylated, amidated form as simply a stronger Semax. The defensible statement is narrower: it is a more enzymatically stable Semax.

The gap that matters most

There is a practical point that outranks all of the chemistry above. The Russian preclinical and clinical literature was done on Semax. Not on this.

Decades of behavioural work, the gene-expression studies, the clinical research that underpins the Russian registration — all of it used the unmodified heptapeptide. The double-capped analogue has no comparable body of published work of its own, no clinical literature, and no registration anywhere in the world. No regulator has reviewed it. Its case rests on a general principle of peptide chemistry plus the assumption that everything established about the parent molecule carries across unchanged, which is precisely the assumption a terminal modification puts in question.

That is not an argument that the modified form is uninteresting. It is an argument about which molecule a given question needs.

Which molecule a question needs

If a protocol is replicating or extending published Semax work, the molecule that work used is Semax — the sequence, the stability profile and the literature all line up. Semax is supplied here as Semax.

If the question is specifically about enzymatic degradation as the limiting variable, the capped analogue is the chemically relevant comparison, and a study designed around it would be generating its own evidence rather than inheriting any.

One point about the source literature is worth stating as a fact about those studies: the Russian Semax research used an intranasal route throughout. Semax is one of the few research peptides where that was the historically primary route rather than an alternative to something else, which is relevant when reading how the published work was designed. Nothing here is medical, dosing, or therapeutic guidance.

Common questions

Is N-Acetyl Semax Amidate stronger than Semax? It is more resistant to enzymatic degradation, which is a claim about stability rather than potency. Whether the terminal modifications alter receptor activity is not firmly established in published work. Treat supplier claims of greater potency with scepticism.

What do the modifications actually do? N-terminal acetylation blocks aminopeptidase cleavage; C-terminal amidation blocks carboxypeptidase cleavage. Each also neutralises a terminal charge. The backbone between them is identical to Semax.

Why does it have no CAS number? Because it is recent. Semax has been in the literature since the 1990s and carries CAS 80714-61-0; the acetylated, amidated form is identified by its PubChem entry (CID 172638603) and formula instead. The absence is a marker of how thin the paper trail is.

Is either form approved as a medicine? Semax is registered in Russia only, and nowhere else. The acetylated, amidated form is registered nowhere at all. Neither is approved in Canada, the United States or the EU, and material supplied here is for laboratory use.

All products sold by NovaEvum are for research and laboratory use only. They are not intended for human or animal consumption, diagnosis, treatment, cure, or prevention of any disease.